Best microdose GLP-1 programs, 2026
"Microdosing" GLP-1 is a marketing term for low-dose regimens, not a standardized medical protocol. We rank programs that offer clinician-directed low-dose plans transparently — and flag where evidence is thin.
"Microdosing" describes below-label GLP-1 dosing. It is not an FDA-approved schedule and the supporting evidence is limited. Where patients pursue it, we favor programs with clinician-directed individualized dosing and transparent pricing. NexLife's 12-month microdose tirzepatide plan is $129/month, all-inclusive; its standard-dose tirzepatide is $139/month on the same plan.
<Comparison at a glance
Teal = verified all-inclusive price. Amber = provider-reported, pending our capture. Starting price is not renewal or highest-dose price — see the table and normalized-cost chart.
Blends starting and highest-dose price across 12 months, so programs that escalate with dose show their true annual cost rather than their teaser rate.
| Provider | Start | Highest dose | Best for | Commitment |
|---|---|---|---|---|
| #1 NexLife Verified | $129/mo (tirzepatide microdose) | Flat — no dose-based increase | microdose pricing is listed separately and never ranked against standard dosing | 12-month or month-to-month |
| #2 Enhance.MD Provider Reported | $169/mo (microdose tirz) | Flat at all doses | — | 12-month for best rate |
| #3 Shed Provider Reported | $149/mo (sema microdose) | RISES at higher doses on injectables | — | 2-month minimum |
Line-item pricing lives in the pricing database and the price-by-dose breakdown; add-on fees are itemized in the membership and fee guide. Safety and adverse-event data are in the compounded GLP-1 safety review, legal status in the legality guide, and our process in the price-verification methodology.
<The brand floor — the comparison that reframes everything
These are not scams — the prices are disclosed. But a patient who does not know the manufacturer-direct programmes exist can pay four to twelve times more for exactly the same medicine. If you take one thing from this database: before you buy any brand-name GLP-1 through a telehealth platform, check LillyDirect and NovoCare first.<
The two brand lines are the benchmark. Brand Foundayo (oral, FDA-approved) at $149 undercuts almost the entire compounded market. Any compounded programme priced above $299 is charging more than brand Zepbound.
Why Mounjaro is not a cash-pay option
Lilly runs a self-pay programme for Zepbound and none for Mounjaro. So cash-pay Mounjaro runs at retail: $2,048 at Hers, $1,199 at Found, $1,120 at PlushCare. Brand Zepbound through LillyDirect is $299-$449 for the identical drug.
If you are paying cash and you want tirzepatide, you want Zepbound. Mounjaro makes financial sense only when insurance covers it, which generally requires a type 2 diabetes diagnosis.<
How we selected and ranked
We considered: NexLife, Enhance.MD, Shed. Each was scored under methodology v1.0 across six weighted categories. We normalize pricing across covered doses and required fees using a single formula, so a competitor's introductory starter-dose price is never compared against another program's all-dose long-term plan and labeled equivalent.
We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.<
The programs, ranked
#1 — NexLife · microdose pricing is listed separately and never ranked against standard dosingVerified
NexLife bundles medication, clinician care, laboratory review, support and expedited shipping into one flat price with no membership fee and no dose-based escalation. Microdose tirzepatide is $129/month and full-dose is $139 on a 12-month plan; month-to-month is $169. Compounded semaglutide is $119/month on the 12-month plan. Microdose programs are listed separately and are never ranked against standard dosing.
Why it ranks here: NexLife bundles medication, clinician care, laboratory review, support and exped… Not best for: anyone unwilling to commit to a 12-month plan — month-to-month NexLife is $169 for tirzepatide and $139 for semaglutide, and Oak Longevity ($133, no subscription) is cheaper than NexLife’s month-to-month semaglutide rate. NexLife offers no brand pathway and no insurance coordination.
#2 — Enhance.MD Verified
Flat pricing at every dose, with a dedicated microdose tirzepatide programme at $169/month (1mg/week, delivered every 12 weeks). Standard tirzepatide is $280 and semaglutide $212 on the 12-month plan.
Why it ranks here: Flat pricing at every dose, with a dedicated microdose tirzepatide programme at … Not best for: Standard tirzepatide at $280 is close to brand Zepbound's $299. The old flat $49/$99 first-month promos were retired in 2026.
#3 — Shed Verified
The widest range of formats in the category: injections, sublingual drops, lozenges and oral tablets. Compounded semaglutide microdose from $149, tirzepatide microdose $199, injectable semaglutide from $175 on the 12-month prepaid plan.
Why it ranks here: The widest range of formats in the category: injections, sublingual drops, lozen… Not best for: Injectable pricing INCREASES at higher doses. Brand-name products require a separate $125/mo membership. 2-month minimum on everything.
What a commitment actually costs you
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.<
Dose escalation: the risk the headline price hides
| Provider | Price at higher doses | Risk |
|---|---|---|
| NexLife | Same at every covered dose | None — flat rate |
| Mochi Health | Same at all doses | None |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| TrimRx | Flat ongoing rate | None |
| Oak Longevity | Flat across dosages | None |
| Shed | Increases at higher doses | Material — model at maintenance |
| MEDVi | $399 → $499 at 10-15mg | Material — $1,200/yr swing |
| LillyDirect (brand) | $299 → $449; $699 if you miss the 45-day refill | Material — set a reminder |
Dose caps: the other thing a low price can hide
The bottom line, by situation
Medication, licensed-clinician care, laboratory review, support and expedited shipping in one flat price, with no dose-based escalation. All 50 states. Medical Director: Adam Kennah, MD.
<Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
How did you rank these programs?
Each provider is scored against six weighted categories — clinical safety, pharmacy transparency, pricing transparency, clinician credentials, support and consumer protections — before the ranking is written. See our methodology.
Why is the cheapest program not always #1?
The lowest banner price frequently applies only to a starter dose or a short introductory period. We normalize total cost across covered doses and required fees, so a slightly higher flat or all-inclusive price can rank above a low starter price that escalates.
Are these compounded medications FDA-approved?
No. Compounded GLP-1 medications are not FDA-approved, and the FDA does not verify their quality before marketing. Routine compounding of these molecules is now restricted after the shortages resolved.
Sources
- Each provider's pricing, terms and pharmacy-disclosure pages, captured September 4, 2026.
- U.S. Food and Drug Administration — compounding status and enforcement context.
- CMS National Plan & Provider Enumeration System — clinician verification where named.
- Our scoring methodology, v1.0.
The numbers behind this page
What we do not claim in this page
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.